Accessibility Menu
Lotus Pharmaceuticals logo

Lotus Pharmaceuticals(OTC) LTUS

Market Cap$89.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-100%
5 Year-89%
1 Year-50%
1 Month+7%
$0.00
+12.50%
+0.00Today
Lotus Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-25
Lotus Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.79%USD 0.002026-08-18
1 month+6.67%USD 0.002026-07-16
3 month-11.11%USD 0.002026-05-26
Year to date+6.67%USD 0.002025-12-31
1 year-49.61%USD 0.012025-08-25
3 year-28.89%USD 0.002023-08-23
5 year-89.33%USD 0.032021-08-24
Since inception-99.96%USD 8.002006-10-04

Lotus Pharmaceuticals Financials at a Glance

Market Cap

$89.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$30.15K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.44 (Low)

Price

$0.00

Volume

35,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Aug 12, 2026

LTUS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lotus Pharmaceuticals

Lotus Pharmaceuticals, Inc. is a healthcare company based in Nashville, Tennessee, focusing on the pharmaceutical sector. The company previously engaged in the development, production, and distribution of pharmaceutical products primarily in China.

Products and Services
  • Pharmaceutical product development and distribution
  • Focus on healthcare solutions in the medical sector
  • Research initiatives aimed at innovative drug formulations
Growth Outlook
  • Recent strategic shifts may open new market opportunities
  • Potential for expansion in the U.S. pharmaceutical market
  • Focus on innovative drug development could enhance competitive edge
Financial Highlights
  • Recent quarterly net income of -$4,737 indicates ongoing operational challenges
  • Trailing twelve months (TTM) revenue remains at $0, reflecting current business status
  • Cash and cash equivalents decreased to $419, highlighting liquidity concerns
Lotus Pharmaceuticals, Inc. currently operates without substantial business activities, which may raise concerns for potential investors. The company has reported no revenue in recent quarters, and the net income figures indicate ongoing operational losses. The recent quarterly financials show a net income of -$4,737, which reflects the challenges faced in maintaining operational viability. Despite these challenges, the company is exploring avenues for growth, particularly in the U.S. pharmaceutical market. The strategic focus on innovative drug development may provide opportunities for future expansion. However, the current financial position, characterized by a decrease in cash reserves, suggests that careful consideration is necessary when evaluating the company's potential. Investors may find the company's efforts to pivot and adapt to new market conditions noteworthy, but the lack of revenue and ongoing losses present significant risks. The future trajectory of Lotus Pharmaceuticals will depend on its ability to successfully implement its growth strategies and improve its financial health.
AI Generated • Aug 8, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

13

CEO

Georgene Rivers

Website

lotuspharmaceuticalsusa.com

Headquarters

Irvine, CA 92618, US

LTUS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

0.00%

Return on Capital

-510.84%

Return on Assets

0.00%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$89.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

27.82M

Volume

35.00K

Avg. Volume

5.88K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$30.15K

EBITDA

-$30.15K

Operating Cash Flow

-$16.40K

Capital Expenditure

$0.00

Free Cash Flow

-$16.40K

Cash & ST Invst.

$419.00

Total Debt

$123.43K

Lotus Pharmaceuticals Performance Analysis

Lotus Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Lotus Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Lotus Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.00N/A
20232023-12-31USD 0.00N/A
20242024-12-31USD 0.00N/A
20252025-12-31USD 0.00N/A
Lotus Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$89.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$381.97

N/A

Employees

233

N/A

Net Income

-$2.78K

+56.6%

EBITDA

-$2.78K

+56.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$419.00

+122.9%

Total Debt

$123.43K

+15.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$123.43K

+15.6%

Return on Assets

0.00%

N/A

Return on Invested Capital

0.00%

N/A

Free Cash Flow

-$3.85K

+41.5%

Operating Cash Flow

-$3.85K

+41.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AWWIAlpha Wastewater, Inc.
$0.00+0.00%
CDSGChina Dongsheng International, Inc.
$0.00-4.17%
MNZOManzo Pharmaceuticals, Inc.
$0.00+0.00%
AWONA1 Group, Inc.
$0.00-5.56%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.82-0.03%
BITOProShares Trust - ProShares Bitcoin ETF
$10.60-0.01%
NVDANvidia
$210.58-0.01%
CRECre8 Enterprise
$6.27+1.44%

Questions About LTUS

What is the current price of Lotus Pharmaceuticals?

Lotus Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Lotus Pharmaceuticals?

Over the past 52 weeks, Lotus Pharmaceuticals has traded between $0.00 and $0.01.

How much debt does Lotus Pharmaceuticals have?

As of the most recent reporting period, Lotus Pharmaceuticals reported total debt of $309.72K.

How much cash does Lotus Pharmaceuticals have on hand?

Lotus Pharmaceuticals reported $1.45K in cash and cash equivalents in its most recent financial results.

What is Lotus Pharmaceuticals’s dividend yield?

Lotus Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services